An enzyme-linked immunosorbent assay (ELISA) targeting LABD97 immunoglobulin G increased the sensitivity of serologic testing for bullous pemphigoid, according to a study published online on October 13, 2026, in the Journal of the American Academy of Dermatology.

The paper, authored by Jeremy P. Snook, Mazdak A. Khalighi, Margaret M. Cocks, and John J. Zone, addresses a recognized gap in the diagnosis of bullous pemphigoid (an autoimmune subepidermal blistering disease most common in older adults). Standard commercial ELISA platforms detect antibodies against BP180 and BP230, the two hallmark autoantigens of the disease. Those assays, however, miss a fraction of patients whose disease is clinically and histologically consistent with bullous pemphigoid.

What does the new assay change?

The authors report that adding LABD97 as an ELISA target raises the sensitivity of serologic testing compared with the existing antigen panel. LABD97 (a 97-kDa antigen of the linear IgA bullous dermatosis spectrum, recognized by both IgA and IgG class antibodies) has an established relationship with the bullous pemphigoid antigen complex. That biochemical overlap is the rationale for testing whether IgG reactivity to LABD97 captures patients the BP180/BP230 assays leave undetected.

The headline claim is a sensitivity gain. The published abstract available to this newsroom does not report the magnitude of that gain, the size of the cohort, or the specificity of the added target. Those figures will determine whether the assay is a diagnostic adjunct or a replacement panel component. Sensitivity bought at the cost of specificity would create false-positive serology in a disease where direct immunofluorescence remains the confirmatory gold standard.

Why diagnostic sensitivity matters here

Bullous pemphigoid is the most common autoimmune blistering disorder in elderly patients, and delayed diagnosis carries real costs: prolonged pruritus, blistering, and exposure to systemic corticosteroids in a population with multiple comorbidities. Serologic assays that are negative despite active disease can delay treatment or push clinicians toward more invasive biopsy-based workups.

Any incremental sensitivity in a blood-based test therefore has practical weight in the clinic. A LABD97 IgG ELISA, run alongside or after standard BP180 and BP230 testing, could identify seronegative-by-conventional-panel patients without an additional procedure. Whether that workflow is cost-effective depends on the prevalence of LABD97-only reactivity in the tested population — a figure the study will need to specify.

What remains unconfirmed

Several clinically decisive parameters are not stated in the available publication record. The study design — retrospective cohort, prospective validation, or cross-sectional analytical study — is not specified in the abstract listing. Headline sensitivity numbers, confidence intervals, and the assay's performance against direct immunofluorescence are likewise absent from the summary available at publication date.

Commercial availability is another open question. An assay described in a methods paper is not yet a test a dermatologist can order; regulatory clearance, kit manufacturing, and reference-laboratory adoption typically follow journal publication by one to three years.

For dermatologists who manage autoimmune blistering disease, the immediate takeaway is directional rather than operational: the antigen universe of bullous pemphigoid serology is wider than BP180 and BP230, and LABD97 IgG reactivity appears to be one of the missing pieces. Clinicians should read the full results section — not the abstract — before extrapolating to their seronegative patients.

If subsequent validation confirms the sensitivity gain with acceptable specificity, LABD97 IgG ELISA could narrow the seronegative gap in bullous pemphigoid diagnosis and reduce reliance on biopsy in frail elderly patients.